FI924982A7 - Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta - Google Patents

Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta Download PDF

Info

Publication number
FI924982A7
FI924982A7 FI924982A FI924982A FI924982A7 FI 924982 A7 FI924982 A7 FI 924982A7 FI 924982 A FI924982 A FI 924982A FI 924982 A FI924982 A FI 924982A FI 924982 A7 FI924982 A7 FI 924982A7
Authority
FI
Finland
Prior art keywords
freeze
monoclonal antibody
preparation containing
dried preparation
containing monoclonal
Prior art date
Application number
FI924982A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI924982A0 (fi
FI924982L (fi
Inventor
Yasuyuki Kuroiwa
Tamotsu Fukuda
Yukio Shimazaki
Shiro Takagi
Original Assignee
Mitsui Toatsu Chemicals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI924982(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Toatsu Chemicals Incorporated filed Critical Mitsui Toatsu Chemicals Incorporated
Publication of FI924982A0 publication Critical patent/FI924982A0/fi
Publication of FI924982L publication Critical patent/FI924982L/fi
Publication of FI924982A7 publication Critical patent/FI924982A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FI924982A 1991-03-08 1992-02-28 Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta FI924982A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
PCT/JP1992/000226 WO1992015331A1 (en) 1991-03-08 1992-02-28 Lyophilized monoclonal antibody preparation

Publications (3)

Publication Number Publication Date
FI924982A0 FI924982A0 (fi) 1992-11-04
FI924982L FI924982L (fi) 1992-11-04
FI924982A7 true FI924982A7 (fi) 1992-11-04

Family

ID=12663510

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924982A FI924982A7 (fi) 1991-03-08 1992-02-28 Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta

Country Status (10)

Country Link
US (1) US5908826A (OSRAM)
EP (2) EP0531539B1 (OSRAM)
JP (1) JPH0565233A (OSRAM)
AU (1) AU645187B2 (OSRAM)
CA (1) CA2082169A1 (OSRAM)
DE (2) DE69225757T2 (OSRAM)
DK (2) DK0531539T3 (OSRAM)
FI (1) FI924982A7 (OSRAM)
NO (1) NO924279L (OSRAM)
WO (1) WO1992015331A1 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2335725B1 (en) 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
US8496930B2 (en) * 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
EP1686137A4 (en) * 2003-10-09 2009-10-28 Chugai Pharmaceutical Co Ltd PROCESS FOR STABILIZING PROTEIN SOLUTIONS
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ES2827180T3 (es) * 2006-10-06 2021-05-20 Amgen Inc Formulaciones de anticuerpos estables
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
UA96473C2 (ru) * 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
HRP20161753T1 (hr) 2010-11-11 2017-02-10 Abbvie Biotechnology Ltd Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
LT3334747T (lt) 2015-08-13 2023-12-27 Amgen Inc. Įkrautas giluminis antigeną surišančio baltymo filtravimas
EP3371189A1 (en) 2015-11-06 2018-09-12 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
US20240417445A1 (en) * 2023-06-13 2024-12-19 Grifols Worldwide Operations Limited Method for producing a lyophilized composition comprising polyclonal igm and composition obtained

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
KR910004868B1 (ko) * 1986-12-15 1991-07-15 미츠이 도아츠 가가쿠 가부시기가이샤 인체 단일 클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료용 약학적 제제
ATE82136T1 (de) * 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
EP0417191B1 (en) * 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
EP0465513A1 (en) * 1989-03-27 1992-01-15 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
FI924982A0 (fi) 1992-11-04
NO924279D0 (no) 1992-11-06
CA2082169A1 (en) 1992-09-09
DE69225757D1 (de) 1998-07-09
JPH0565233A (ja) 1993-03-19
AU1337592A (en) 1992-10-06
EP0531539A1 (en) 1993-03-17
FI924982L (fi) 1992-11-04
DK0841067T3 (da) 2002-07-15
WO1992015331A1 (en) 1992-09-17
DK0531539T3 (da) 1998-10-12
DE69232617T2 (de) 2002-10-31
AU645187B2 (en) 1994-01-06
EP0841067B1 (en) 2002-05-22
EP0531539B1 (en) 1998-06-03
NO924279L (no) 1992-11-06
EP0531539A4 (OSRAM) 1995-04-05
DE69232617D1 (de) 2002-06-27
EP0841067A1 (en) 1998-05-13
DE69225757T2 (de) 1998-12-03
US5908826A (en) 1999-06-01

Similar Documents

Publication Publication Date Title
FI924982A7 (fi) Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta
DK666389A (da) Monoklonalt antistof
FI930580L (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
NZ236000A (en) Oligomeric monoclonal igg antibody composition
FI925631L (fi) Monoklonala antikroppar
IL99363A0 (en) Pharmaceutical compositions comprising homoconjugated monoclonal antibodies
DE68914244D1 (de) Monoklonaler Antikörper.
DK63187A (da) Krydsbeskyttende monoklonale antistofpraeparater
EP0580859A4 (en) Anti-eda monoclonal antibody
NO920523D0 (no) Ige-reseptor-antistoff
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
EP0506523A3 (en) Monoclonal antibodies
DK717888A (da) Monoklonale antistoffer
NO890116D0 (no) Monoklonale antistoffer.
DK474189A (da) Monoklonalt antistof
DK370089D0 (da) Anti-urokinase monoklonale antistoffer
DE69023717D1 (de) Monoklonaler Antikörper.
DK413389D0 (da) Monoklonale antistoffer
NO924803D0 (no) Tumor-relatert monoklonalt antistoff 88bv59
FI935038L (fi) Tumoer associerad monoklonal antikropp 81av78
DK220688D0 (da) Monoklonalt antistof
SE9002605D0 (sv) Antikroppssubstans
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
ITMI910660A0 (it) Anticorpi monoclonali come antidoti
SE9002479D0 (sv) Antibody conjugates

Legal Events

Date Code Title Description
FD Application lapsed